^
    Back
    Association details:
    Biomarker:BAP1 deletion
    Cancer:Malignant Pleural Mesothelioma
    Drug:pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Thorac Oncol
    Title:

    BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study

    Published date:
    04/27/2022
    Excerpt:
    First-line platinum and pemetrexed-treated patients with BAP1 loss had significantly longer median survival than those with retained BAP1 in both the Danish (20.1 versus 7.3 mo, p < 0.001) and Australian cohorts (19.6 versus 11.1 mo, p < 0.01)….BAP1 is a predictive biomarker for survival after first-line combination platinum and pemetrexed chemotherapy and a potential prognostic marker in PM.
    Secondary therapy:
    Chemotherapy
    DOI:
    https://doi.org/10.1016/j.jtho.2022.04.008